Literature DB >> 25535865

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.

Andre Larochelle1, J Joseph Melenhorst1, Sawa Ito1, A John Barrett1, Amalia Dutra2, Evgenia Pak2, Samantha Miner1, Keyvan Keyvanfar1, Nancy F Hensel1, Katayoun Rezvani3, Pawel Muranski1, Paul Liu4.   

Abstract

Mesenchymal stromal cells (MSCs) support the growth and differentiation of normal hematopoietic stem cells (HSCs). Here we studied the ability of MSCs to support the growth and survival of leukemic stem cells (LSCs) in vitro. Primary leukemic blasts isolated from the peripheral blood of 8 patients with acute myeloid leukemia (AML) were co-cultured with equal numbers of irradiated MSCs derived from unrelated donor bone marrow, with or without cytokines for up to 6weeks. Four samples showed CD34(+)CD38(-) predominance, and four were predominantly CD34(+)CD38(+). CD34(+) CD38(-) predominant leukemia cells maintained the CD34(+) CD38(-) phenotype and were viable for 6weeks when co-cultured with MSCs compared to co-cultures with cytokines or medium only, which showed rapid differentiation and loss of the LSC phenotype. In contrast, CD34(+) CD38(+) predominant leukemic cells maintained the CD34(+)CD38(+) phenotype when co-cultured with MSCs alone, but no culture conditions supported survival beyond 4weeks. Cell cycle analysis showed that MSCs maintained a higher proportion of CD34(+) blasts in G0 than leukemic cells cultured with cytokines. AML blasts maintained in culture with MSCs for up to 6weeks engrafted NSG mice with the same efficiency as their non-cultured counterparts, and the original karyotype persisted after co-culture. Chemosensitivity and transwell assays suggest that MSCs provide pro-survival benefits to leukemic blasts through cell-cell contact. We conclude that MSCs support long-term maintenance of LSCs in vitro. This simple and inexpensive approach will facilitate basic investigation of LSCs and enable screening of novel therapeutic agents targeting LSCs. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25535865      PMCID: PMC4634876          DOI: 10.1016/j.scr.2014.11.007

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  16 in total

1.  Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.

Authors:  Yoriko Saito; Hiroshi Kitamura; Atsushi Hijikata; Mariko Tomizawa-Murasawa; Satoshi Tanaka; Shinsuke Takagi; Naoyuki Uchida; Nahoko Suzuki; Akiko Sone; Yuho Najima; Hidetoshi Ozawa; Atsushi Wake; Shuichi Taniguchi; Leonard D Shultz; Osamu Ohara; Fumihiko Ishikawa
Journal:  Sci Transl Med       Date:  2010-02-03       Impact factor: 17.956

Review 2.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

3.  A newly discovered class of human hematopoietic cells with SCID-repopulating activity.

Authors:  M Bhatia; D Bonnet; B Murdoch; O I Gan; J E Dick
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

4.  Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.

Authors:  Andrew J Gentles; Sylvia K Plevritis; Ravindra Majeti; Ash A Alizadeh
Journal:  JAMA       Date:  2010-12-22       Impact factor: 56.272

5.  Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells.

Authors:  S N Robinson; J Ng; T Niu; H Yang; J D McMannis; S Karandish; I Kaur; P Fu; M Del Angel; R Messinger; F Flagge; M de Lima; W Decker; D Xing; R Champlin; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2006-02       Impact factor: 5.483

6.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.

Authors:  T Lapidot; C Sirard; J Vormoor; B Murdoch; T Hoang; J Caceres-Cortes; M Minden; B Paterson; M A Caligiuri; J E Dick
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

7.  A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.

Authors:  Yoriko Saito; Hitomi Yuki; Mitsuo Kuratani; Yoshinobu Hashizume; Shinsuke Takagi; Teruki Honma; Akiko Tanaka; Mikako Shirouzu; Junko Mikuni; Noriko Handa; Ikuko Ogahara; Akiko Sone; Yuho Najima; Yuri Tomabechi; Motoaki Wakiyama; Naoyuki Uchida; Mariko Tomizawa-Murasawa; Akiko Kaneko; Satoshi Tanaka; Nahoko Suzuki; Hiroshi Kajita; Yuki Aoki; Osamu Ohara; Leonard D Shultz; Takehiro Fukami; Toshio Goto; Shuichi Taniguchi; Shigeyuki Yokoyama; Fumihiko Ishikawa
Journal:  Sci Transl Med       Date:  2013-04-17       Impact factor: 17.956

Review 8.  Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia.

Authors:  J A Kennedy; F Barabé
Journal:  Leukemia       Date:  2008-08-07       Impact factor: 11.528

9.  Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells.

Authors:  Djoke van Gosliga; Hein Schepers; Aleksandra Rizo; Dorina van der Kolk; Edo Vellenga; Jan Jacob Schuringa
Journal:  Exp Hematol       Date:  2007-10       Impact factor: 3.084

Review 10.  Stem cell concepts renew cancer research.

Authors:  John E Dick
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

View more
  21 in total

1.  CD99 is a therapeutic target on disease stem cells in myeloid malignancies.

Authors:  Stephen S Chung; William S Eng; Wenhuo Hu; Mona Khalaj; Francine E Garrett-Bakelman; Montreh Tavakkoli; Ross L Levine; Martin Carroll; Virginia M Klimek; Ari M Melnick; Christopher Y Park
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

Review 2.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

3.  Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.

Authors:  Rohtesh S Mehta; Xiaohua Chen; Jeyaraj Antony; Michael Boyiadzis; Paul Szabolcs
Journal:  J Immunother       Date:  2016 Feb-Mar       Impact factor: 4.456

4.  Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.

Authors:  Rafael Diaz de la Guardia; Belen Lopez-Millan; Heleia Roca-Ho; Clara Bueno; Francisco Gutiérrez-Agüera; Jose Luis Fuster; Eduardo Anguita; Samanta Romina Zanetti; Susana Vives; Josep Nomdedeu; Robert Sackstein; Jessie Lavoie; Elena Gónzalez-Rey; Mario Delgado; Michael Rosu-Myles; Pablo Menendez
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

5.  Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches.

Authors:  Andrés García-García; Thibaut Klein; Gordian Born; Morgane Hilpert; Arnaud Scherberich; Claudia Lengerke; Radek C Skoda; Paul E Bourgine; Ivan Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-05       Impact factor: 11.205

Review 6.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

7.  Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia.

Authors:  Paul Takam Kamga; Giulio Bassi; Adriana Cassaro; Martina Midolo; Mariano Di Trapani; Alessandro Gatti; Roberta Carusone; Federica Resci; Omar Perbellini; Michele Gottardi; Massimiliano Bonifacio; Armel Hervé Nwabo Kamdje; Achille Ambrosetti; Mauro Krampera
Journal:  Oncotarget       Date:  2016-04-19

8.  Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.

Authors:  Annette K Brenner; Ina Nepstad; Øystein Bruserud
Journal:  Front Immunol       Date:  2017-02-09       Impact factor: 7.561

Review 9.  Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia.

Authors:  Federico Mosna; Michele Gottardi
Journal:  Stem Cells Int       Date:  2016-01-13       Impact factor: 5.443

Review 10.  The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Authors:  Silje Johansen; Annette K Brenner; Sushma Bartaula-Brevik; Håkon Reikvam; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.